M. Citron

发表

Alzheimer's disease: strategies for disease modification

M. Citron, Martin Citron, 2010, Nature Reviews Drug Discovery.

Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production.

D. Selkoe, C. Vigo‐Pelfrey, M. Citron, 1992, Nature.

Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE.

J. Treanor, D. Teplow, M. Citron, 1999, Science.

Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation

W. Richards, M. Citron, R. Vassar, 2001, Nature Neuroscience.

Elevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer disease

P. Wong, Rena Li, T. Beach, 2003, Nature Medicine.

The tau positron‐emission tomography tracer AV‐1451 binds with similar affinities to tau fibrils and monoamine oxidases

M. Citron, J. Hannestad, Céline Vermeiren, 2018, Movement disorders : official journal of the Movement Disorder Society.

Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation.

W. Richards, M. Citron, R. Vassar, 2001, Nature neuroscience.

Control of Peripheral Nerve Myelination by the ß-Secretase BACE1

P. Saftig, M. Citron, C. Birchmeier, 2006, Science.

Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice

Weiming Xia, Paul Fraser, J. Rommens, 1997, Nature Medicine.

Passive Immunization with Anti-Tau Antibodies in Two Transgenic Models

P. Davies, M. Hutton, M. Citron, 2011, The Journal of Biological Chemistry.

Fenchylamine sulfonamide inhibitors of amyloid beta peptide production by the gamma-secretase proteolytic pathway: potential small-molecule therapeutic agents for the treatment of Alzheimer's disease.

J. Treanor, G. Rishton, M. Citron, 2000, Journal of medicinal chemistry.

A Furin-like Convertase Mediates Propeptide Cleavage of BACE, the Alzheimer's β-Secretase*

D. Teplow, M. Citron, R. Vassar, 2000, The Journal of Biological Chemistry.

Aβ-Generating Enzymes Recent Advances in β- and γ-Secretase Research

M. Citron, R. Vassar, 2000, Neuron.

The making of a Lewy body: the role of α-synuclein post-fibrillization modifications in regulating the formation and the maturation of pathological inclusions

G. Knott, C. Strand, M. Citron, 2018, bioRxiv.

In vivo cleavage of alpha2,6-sialyltransferase by Alzheimer beta-secretase.

H. Yonekawa, M. Citron, N. Taniguchi, 2005, The Journal of biological chemistry.

Expression of Alzheimer’s Disease-associated Presenilin-1 Is Controlled by Proteolytic Degradation and Complex Formation*

P. Kloetzel, D. Selkoe, M. Citron, 1998, The Journal of Biological Chemistry.

Current directions in tau research: Highlights from Tau 2020

Keith A. Johnson, M. Carrillo, H. Snyder, 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

Alzheimer's disease: treatments in discovery and development

M. Citron, Martin Citron, 2002, Nature Neuroscience.

α-Synuclein fibrillogenesis as target for drug development

M. Citron, L. Narhi, J. Wypych, 2001 .

Central BACE1 inhibition by LY2886721 produces opposing effects on APP processing as reflected by cerebrospinal fluid sAPPalpha and sAPPbeta

R. Dean, M. Citron, P. May, 2012, Alzheimer's & Dementia.

Secretases as targets for the treatment of Alzheimer's disease.

M. Citron, 2000, Molecular medicine today.

Generation of amyloid β protein from its precursor is sequence specific

D. Selkoe, D. Teplow, M. Citron, 1995, Neuron.

Parkinson's disease-associated alpha-synuclein is more fibrillogenic than beta- and gamma-synuclein and cannot cross-seed its homologs.

M. Citron, D. Anafi, L. Narhi, 2000, The Journal of biological chemistry.

Antiparkinsonian effects of the "Radiprodil and Tozadenant" combination in MPTP-treated marmosets

P. Muglia, M. Citron, S. Rose, 2017, PloS one.

Additive Effects of PS1 and APP Mutations on Secretion of the 42-Residue Amyloid β-Protein

D. Selkoe, S. Younkin, M. Citron, 1998, Neurobiology of Disease.

Epitope determines efficacy of therapeutic anti-Tau antibodies in a functional assay with human Alzheimer Tau

Terry S Baker, M. Citron, G. Mairet-Coello, 2018, Acta Neuropathologica.

Polyglutamine Repeat Length-Dependent Proteolysis of Huntingtin

C. Ross, W. Richards, G. Bitan, 2002, Neurobiology of Disease.

Title Polyglutamine repeat length-dependent proteolysis of huntingtin Permalink

C. Ross, W. Richards, G. Bitan, 2002 .

Amyloid Precursor Protein Processing in Sterol Regulatory Element-binding Protein Site 2 Protease-deficient Chinese Hamster Ovary Cells*

Y. Luo, M. Citron, R. Deshpande, 1998, The Journal of Biological Chemistry.

Mechanistic Studies of the Effect of Presenilins 1 and 2 on APP Metabolism

D. Selkoe, C. Lemere, M. Citron, 1998 .

Inhibition of Amyloid β-Protein Production in Neural Cells by the Serine Protease Inhibitor AEBSF

D. Selkoe, D. Teplow, M. Citron, 1996, Neuron.

β-Secretase : Tissue Culture Studies of Sequence Specificity, Inhibitors, and Candidate Enzymes.

M. Citron, 2000, Methods in molecular medicine.

Substitution of phenylalanine by proline at position 19 of amyloid β peptide results in an increased production of amyloid β peptides with alternative N-termini after protein kinase C stimulation

D. Selkoe, D. Teplow, M. Citron, 1996 .

Production of amyloid-β-peptide by cultured cells: No evidence for internal initiation of translation at Met596

D. Selkoe, M. Citron, C. Haass, 1993, Neurobiology of Aging.

Identifying Proteases That Cleave APP

M. Citron, 2000, Annals of the New York Academy of Sciences.

The Vacuolar H-ATPase Inhibitor Bafilomycin A1 Differentially Affects Proteolytic Processing of Mutant and Wild-type -Amyloid Precursor Protein (*)

D. Selkoe, D. Teplow, M. Citron, 1995, The Journal of Biological Chemistry.

Normal Production of the Amyloid β-Protein and the Pathogenesis of Alzheimer’s Disease

D. Selkoe, D. Teplow, M. Citron, 1995 .

A Substrate-Based Difluoro Ketone Selectively Inhibits Alzheimer's γ-Secretase Activity

D. Selkoe, M. Wolfe, M. Citron, 1998 .

A substrate-based difluoro ketone selectively inhibits Alzheimer's gamma-secretase activity.

D. Selkoe, M. Wolfe, M. Citron, 1998, Journal of medicinal chemistry.

A Substrate-Based Difluoro Ketone Selectively Inhibits Alzheimer′s γ-Secretase Activity.

D. Selkoe, M. Wolfe, M. Citron, 1998 .

Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation.

B. Winblad, D. Selkoe, D. Teplow, 1994, Proceedings of the National Academy of Sciences of the United States of America.

beta-Amyloid, protein processing and Alzheimer's disease.

D. Selkoe, D. Teplow, M. Citron, 1995, Arzneimittel-Forschung.

The c4 repressor of bacteriophage P1 is a processed 77 base antisense RNA.

M. Citron, H. Schuster, 1992, Nucleic acids research.

T807, a reported selective tau tracer, binds with nanomolar affinity to monoamine oxidase a

M. Citron, J. Hannestad, Céline Vermeiren, 2015, Alzheimer's & Dementia.

Human beta-secretase and Alzheimer's disease.

M. Citron, 2001, Expert opinion on therapeutic targets.

α-Synuclein Fibrillogenesis Is Nucleation-dependent

M. Citron, J. Wypych, S. Steavenson, 1999, The Journal of Biological Chemistry.

BACE1 Deficiency Rescues Memory Deficits and Cholinergic Dysfunction in a Mouse Model of Alzheimer's Disease

M. Ohno, J. Disterhoft, S. Younkin, 2004, Neuron.

Design and preparation of a potent series of hydroxyethylamine containing β-secretase inhibitors that demonstrate robust reduction of central β-amyloid.

Yuan Cheng, Wenge Zhong, Michael D Bartberger, 2012, Journal of medicinal chemistry.

Amyloid β peptide load is correlated with increased β-secretase activity in sporadic Alzheimer's disease patients

H. Cai, D. Price, P. Wong, 2004 .

Strategies for disease modification in Alzheimer's disease

M. Citron, Martin Citron, Martin Citron, 2004, Nature Reviews Neuroscience.

Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production

D. Selkoe, C. Vigo‐Pelfrey, M. Citron, 1992, Nature.

The Swedish mutation causes early-onset Alzheimer's disease by β-secretase cleavage within the secretory pathway

D. Selkoe, L. Lannfelt, C. Lemere, 1995, Nature Medicine.

Generation of amyloid beta protein from its precursor is sequence specific.

D. Selkoe, D. Teplow, M. Citron, 1995, Neuron.

Transcriptional control via translational repression by c4 antisense RNA of bacteriophages P1 and P7.

M. Citron, H. Schuster, A. Biere, 1992, Genes & development.

The c4 repressors of bacteriophages P1 and P7 are antisense RNAs

M. Citron, H. Schuster, 1990, Cell.

Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor

James E Audia, R. Dean, T. Lindstrom, 2011, The Journal of Neuroscience.

Human β-secretase and Alzheimer’s disease

M. Citron, 2001 .

A Loss of Function Mutation of Presenilin-2 Interferes with Amyloid β-Peptide Production and Notch Signaling*

S. Lincoln, J. Hardy, T. Iwatsubo, 1999, The Journal of Biological Chemistry.

The Proteolytic Fragments of the Alzheimer’s Disease-associated Presenilin-1 Form Heterodimers and Occur as a 100–150-kDa Molecular Mass Complex*

D. Selkoe, K. Beyreuther, M. Citron, 1998, The Journal of Biological Chemistry.

Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease

G. Schellenberg, J. Hardy, M. Viitanen, 1996, Nature Medicine.

Presenilin Proteins Undergo Heterogeneous Endoproteolysis between Thr291and Ala299and Occur as Stable N- and C-Terminal Fragments in Normal and Alzheimer Brain Tissue

R. Sherrington, D. Selkoe, P. Fraser, 1997, Neurobiology of Disease.

Enhanced Production and Oligomerization of the 42-residue Amyloid β-Protein by Chinese Hamster Ovary Cells Stably Expressing Mutant Presenilins*

D. Selkoe, D. Teplow, D. Kholodenko, 1997, The Journal of Biological Chemistry.

Constitutive secretion of tau protein by an unconventional mechanism

M. Citron, Xiyun Chai, J. Dage, 2012, Neurobiology of Disease.

The Biological and Pathological Function of the Presenilin-1 ΔExon 9 Mutation Is Independent of Its Defect to Undergo Proteolytic Processing*

M. Citron, C. Haass, Ralf Baumeister, 1999, The Journal of Biological Chemistry.

Proteolytic processing of the Alzheimer disease-associated presenilin-1 generates an in vivo substrate for protein kinase C.

D. Selkoe, P. George-Hyslop, G. Multhaup, 1997, Proceedings of the National Academy of Sciences of the United States of America.

Anti-Inflammatory Drug Therapy Alters β-Amyloid Processing and Deposition in an Animal Model of Alzheimer's Disease

M. Citron, G. Landreth, Hantao Liu, 2003, The Journal of Neuroscience.

Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1

M. Ohno, J. Disterhoft, Lei Chang, 2006, The European journal of neuroscience.

BACE1 (β-secretase) knockout mice do not acquire compensatory gene expression changes or develop neural lesions over time

M. Citron, Hantao Liu, M. Damore, 2003, Neurobiology of Disease.

Expression Analysis of BACE2 in Brain and Peripheral Tissues*

M. Citron, R. Vassar, B. Bennett, 2000, The Journal of Biological Chemistry.

Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease.

J. Hardy, M. Viitanen, D. Selkoe, 1996, Nature medicine.

Both Familial Parkinson’s Disease Mutations Accelerate α-Synuclein Aggregation*

M. Citron, K. Sitney, D. Anafi, 1999, The Journal of Biological Chemistry.

Characterization of Alzheimer's beta -secretase protein BACE. A pepsin family member with unusual properties.

V. Katta, M. Citron, R. Vassar, 2000 .

β‐secretase as a target for the treatment of Alzheimer's disease

M. Citron, 2002 .

Characterization of Alzheimer's β-Secretase Protein BACE

V. Katta, M. Citron, R. Vassar, 2000, The Journal of Biological Chemistry.

β‐Secretase cleavage is not required for generation of the intracellular C‐terminal domain of the amyloid precursor family of proteins

D. Selkoe, D. Walsh, J. Fadeeva, 2010, The FEBS journal.

β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Levels Become Elevated in Neurons around Amyloid Plaques: Implications for Alzheimer's Disease Pathogenesis

R. Berry, M. Citron, Marina V. Yasvoina, 2007, The Journal of Neuroscience.

Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis.

R. Berry, M. Citron, Marina V. Yasvoina, 2007, The Journal of neuroscience : the official journal of the Society for Neuroscience.

Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients.

H. Cai, P. Wong, Rena Li, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Emerging Alzheimer's disease therapies: inhibition of beta-secretase.

M. Citron, 2002, Neurobiology of aging.

Emerging Alzheimer’s disease therapies: inhibition of β-secretase

M. Citron, Martin Citron, 2002, Neurobiology of Aging.

Activation of protein kinase C inhibits cellular production of the amyloid beta-protein.

J. Growdon, D. Selkoe, R. Wurtman, 1993, The Journal of biological chemistry.

Beta-secretase inhibition for the treatment of Alzheimer's disease--promise and challenge.

M. Citron, 2004, Trends in pharmacological sciences.

BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice

M. Ohno, J. Disterhoft, R. Berry, 2007, Neurobiology of Disease.

Evidence that the 42- and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activities.

D. Selkoe, M. Citron, P. Seubert, 1996, Proceedings of the National Academy of Sciences of the United States of America.

alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease.

M. Citron, J. Wypych, S. Steavenson, 1999, The Journal of biological chemistry.

Title beta-secretase cleavage of Alzheimer ' s amyloid precursor protein by the transmembrane aspartic protease

J. Treanor, D. Teplow, M. Citron, 2015 .

BACE inhibitor LY2886721 safety and central and peripheral PK and PD in healthy subjects (HSs)

R. Dean, M. Citron, L. Ereshefsky, 2012, Alzheimer's & Dementia.

Central and Peripheral Pharmacokinetic and Pharmacodynamic Effects of the β-site APP Cleavage Enzyme (BACE1) Inhibitor LY2811376 In Humans

R. Dean, M. Citron, L. Ereshefsky, 2010, Alzheimer's & Dementia.

Abeta-generating enzymes: recent advances in beta- and gamma-secretase research.

M. Citron, R. Vassar, M Citron, 2000, Neuron.

Second-site suppressors of the bacteriophage P1 virs mutant reveal the interdependence of the c4, icd, and ant genes in the P1 immI operon

M. Citron, H. Schuster, A. Günther, 1994, Journal of bacteriology.

Hydroxyethylamine-based inhibitors of BACE1: P₁-P₃ macrocyclization can improve potency, selectivity, and cell activity.

R. Wahl, S. Hitchcock, M. Citron, 2013, Bioorganic & medicinal chemistry letters.

A Potent and Orally Efficacious, Hydroxyethylamine-Based Inhibitor of β-Secretase.

Yuan Cheng, Yi Luo, Wenge Zhong, 2012, ACS medicinal chemistry letters.

Design and synthesis of potent, orally efficacious hydroxyethylamine derived β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors.

R. Wahl, S. Hitchcock, Yuan Cheng, 2012, Journal of medicinal chemistry.

The Role of APP Processing and Trafficking Pathways in the Formation of Amyloid β‐Protein a

D. Selkoe, D. Teplow, M. Citron, 1996 .

The role of APP processing and trafficking pathways in the formation of amyloid beta-protein.

D. Selkoe, D. Teplow, M. Citron, 1996, Annals of the New York Academy of Sciences.

Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody

L. Buée, I. Landrieu, M. Citron, 2019, Brain : a journal of neurology.

Preclinical characterization of LY2886721: A BACE1 inhibitor in clinical development for early Alzheimer's disease

T. Lindstrom, M. Citron, P. May, 2012, Alzheimer's & Dementia.

Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease alpha-synuclein fibrillogenesis.

Theodore W Randolph, Brent S Kendrick, Eva Y Chi, 2003, Biochemistry.

_-secretase – progress and questions

M. Citron, 2005 .

Amyloidogenic function of the Alzheimer's disease-associated presenilin 1 in the absence of endoproteolysis.

M. Citron, H. Loetscher, C. Haass, 1999, Biochemistry.

Involvement of β-site APP cleaving enzyme 1 (BACE1) in amyloid precursor protein-mediated enhancement of memory and activity-dependent synaptic plasticity

A. Delacourte, S. Younkin, L. Younkin, 2007, Proceedings of the National Academy of Sciences.

Parkinson's Disease-associated α-Synuclein Is More Fibrillogenic than β- and γ-Synuclein and Cannot Cross-seed Its Homologs*

M. Citron, D. Anafi, L. Narhi, 2000, The Journal of Biological Chemistry.

Characterization of Alzheimer's β-secretase protein bace: A pepsin family member with unusual properties

M. Citron, R. Vassar, B. Bennett, 2000, Neurobiology of Aging.

a-Synuclein Fibrillogenesis Is Nucleation-dependent IMPLICATIONS FOR THE PATHOGENESIS OF PARKINSON 9 S DISEASE

M. Citron, J. Wypych, S. Steavenson, 1999 .

Establishing the Relationship between In Vitro Potency, Pharmacokinetic, and Pharmacodynamic Parameters in a Series of Orally Available, Hydroxyethylamine-Derived β-Secretase Inhibitors

S. Hitchcock, M. Citron, S. Babu-Khan, 2012, Journal of Pharmacology and Experimental Therapeutics.

β-Secretase — A Target for Alzheimer’s Disease

M. Citron, 2002 .

Three additional operators, Op21, Op68, and Op88, of bacteriophage P1. Evidence for control of the P1 dam methylase by Op68.

M. Citron, H. Schuster, M. Velleman, 1989, The Journal of biological chemistry.

In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson’s disease

M. Citron, D. Bonhaus, M. Bani, 2023, NPJ Parkinson's disease.

In Vivo Cleavage of α2,6-Sialyltransferase by Alzheimer β-Secretase*

H. Yonekawa, M. Citron, N. Taniguchi, 2005, Journal of Biological Chemistry.

Beta-secretase as a target for the treatment of Alzheimer's disease.

M. Citron, 2002, Journal of neuroscience research.

β-Secretase: Progress and Open Questions

M. Citron, 2013 .

Constitutive secretion of tau protein by an unconventional mechanism

M. Citron, Xiyun Chai, J. Dage, 2012, Neurobiology of Disease.